Figure 4

Figure 4

Rhoifolin (Rho: 1, 3, and 5 μg/L) improved memory in the novel object recognition test (NOR). (A) Representative locomotion tracking pattern of the control, scopolamine (Sco: 100 µM), rhoifolin (Rho: 1, 3, and 5 µg/L), and galantamine (GAL: 1 mg/L) treated groups. (B) Representation of the percentages of preference in different groups. (C) Representation of the exploratory time in different groups. Values are means ± S.E.M. (n = 10). For Tukey’s post hoc analyses: (B) Control vs. Sco (100 µM): # p < 0.01, Sco vs. Rho (3 µg/L): # p < 0.01, and Sco vs. Rho (5 µg/L): # p < 0.01; (C) Control vs. Sco (100 µM): # p < 0.01, Sco vs. Rho (1 µg/L): ### p < 0.0001, Sco vs. Rho (3 µg/L): ### p < 0.0001, and Sco vs. Rho (5 µg/L): ### p < 0.0001.